Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Inclusion Criteria: 1. Female subjects between, and including, 18 and 45 years of age at the first vaccination; 2. Healthy subjects as established by medical history and history-oriented clinical examination; 3. Be able to understand and comply with the request of the protocol; 4. Without acute cervicitis; 5. Not pregnant; 6. Have intact cervix. Exclusion Criteria: 1. Use of any investigational or non-registered product (drug or vaccine)within 30 days preceding the first vaccination, or plan to use during the study period; 2. Are using immunosuppressants; 3. Administration of immunoglobulin and/or any blood products within the three months preceding the first vaccination or planned administration during the study period; 4. Vaccinated of inactivated vaccine 14 days or attenuated vaccine 21 days before the enrollment; 5. Fever; 6. Concurrently participating another clinical trial; 7. Has received vaccines against HPV 16/18 ; 8. Immunodeficient; 9. History of allergic disease; 10. Serious medical disorders; 11. Blood coagulation disorders; 12. Epilepsy; 13. Unable to comply with protocol due to the mental illness; 14. Visible Condyloma; 15. Pregnant or breast-feeding women; 16. vergins; 17. Have more than 4 sexual partners.